Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.
Y, Y., L, L., X, L., X, Z., & H, X. (2026). Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.. Frontiers in endocrinology. https://doi.org/10.3389/fendo.2026.1900132
Y Y, L L, X L, X Z, H X. Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.. Frontiers in endocrinology. 2026; doi: 10.3389/fendo.2026.1900132
Y Y, L L, X L, et al. Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.[J]. Frontiers in endocrinology. 2026. DOI: 10.3389/fendo.2026.1900132.
@article{y2026,
author = {Yang Y and Liu L and Liang X and Zhang X and Xu H},
title = {Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI.},
journal = {Frontiers in endocrinology},
year = {2026},
doi = {10.3389/fendo.2026.1900132},
note = {PMID: 42630147},
}
TY - JOUR AU - Yang Y AU - Liu L AU - Liang X AU - Zhang X AU - Xu H TI - Association of the TyG index and inflammatory burden index with AMR-defined coronary microvascular dysfunction and 12-month MACE after STEMI. T2 - Frontiers in endocrinology PY - 2026 DO - 10.3389/fendo.2026.1900132 AN - PMID:42630147 ER -
BACKGROUND: Metabolic dysfunction and inflammation may jointly contribute to coronary microvascular injury and adverse outcomes after primary percutaneous coronary intervention (PPCI) for ST-segment elevation myocardial infarction (STEMI). We examined the independent and combined associations of the triglyceride-glucose (TyG) index and inflammatory burden index (IBI) with angiographic microvascular resistance (AMR)-defined coronary microvascular dysfunction (CMD), their incremental value beyond conventional factors, and their associations with 12-month major adverse cardiovascular events (MACE). METHODS: In this retrospective cohort study conducted at a single center, 318 STEMI patients who underwent PPCI and achieved a TIMI grade 3 flow post-procedure were enrolled. AMR was derived from the final post-PPCI angiogram of the culprit vessel, and CMD was defined as AMR >26.6 mmHg·s/dm. Multivariable models assessed associations with CMD and MACE. Sequential models evaluated the incremental performance of TyG and IBI with 1,000-resample bootstrap internal validation. RESULTS: CMD was present in 102/318 (32.1%). TyG (OR per 1-unit, 3.83; 95% CI, 2.04-7.21; P<0.001) and IBI (OR per 10-units, 1.13; 95% CI, 1.07-1.20; P<0.001) were independently associated with CMD. The TyG-IBI model showed an AUC of 0.773 for CMD; adding both to a clinical/procedural model improved the AUC from 0.904 to 0.939 (bootstrap-validated, 0.920; ΔAUC, 0.036; P = 0.001). Over 12 months, 69 (21.7%) patients had MACE. TyG (HR, 1.97; 95% CI, 1.30-2.98; P = 0.001) and IBI (HR per 10-units, 1.02; 95% CI, 1.00-1.05; P = 0.022) remained independent predictors of MACE, with the highest risk in those with both markers elevated. CONCLUSION: TyG and IBI were independently associated with AMR-defined CMD and 12-month MACE after STEMI. Adding TyG and IBI to conventional clinical and procedural factors improved model discrimination for CMD, although prospective multicenter validation is required before clinical application.